COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series
oleh: Sharon L. Walmsley, Leah Szadkowski, Bradly Wouters, Rosemarie Clarke, Karen Colwill, Paula Rochon, Michael Brudno, Rizanni Ravindran, Janet Raboud, Allison McGeer, Amit Oza, Christopher Graham, Amanda Silva, Dorin Manase, Peter Maksymowsky, Laura Parente, Roaya Monica Dayam, Jacqueline Simpson, Adrian Pasculescu, Anne-Claude Gingras
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2023-04-01 |
Deskripsi
Summary: We report a decentralized prospective cohort study of self-reported adverse events and antibody responses to COVID vaccines derived from dried blood spots. Data are presented for 911 older (aged >70 years) and 375 younger (30–50 years) recruits to 48 weeks after the primary vaccine series. After a single vaccine, 83% younger and 45% older participants had overall seropositivity (p < 0.0001) increasing to 100/98% with the second dose, respectively (p = 0.084). A cancer diagnosis (p = 0.009), no mRNA-1273 vaccine doses (p <0 .0001), and older age (p <0 .0001) predicted lower responses. Antibody levels declined in both cohorts at 12 and 24 weeks increasing with booster doses. At 48 weeks, for participants with 3 vaccine doses, the median antibody levels were higher in the older cohort (p = 0.04) with any dose of mRNA-1273 (p <0 .0001) and with COVID infection (p <0 .001). The vaccines were well tolerated. Breakthrough COVID infections were uncommon (16% older cohort, 29% younger cohort; p < 0.0001) and mild.